Evercore ISI analyst Vijay Kumar downgraded Waters (WAT) to In Line from Outperform with a price target of $270, down from $285. All of the life science tools companies who have reported Q2 results so far this earnings season have missed and lowered guidance and the analyst is assuming Waters and Agilent (A) could see a similar cut to revenue given both have meaningful exposure to China and biopharma, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on WAT:
- Citi lowers Waters target, initiates ‘negative catalyst watch’
- Waters price target lowered to $290 from $325 at Barclays
- Waters, Princeton University announce multi-year research collaboration
- Stifel healthcare analyst to hold an analyst/industry conference call
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue